Fact Sheet
Prior Authorizations and Step Therapy Impact to Patients in Specialty Markets
The analytics used in this publication were originally commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Jun 24, 2020
Utilization management restrictions are common across a variety of therapeutic areas, but treatments for managing rheumatoid arthritis (RA) and multiple sclerosis (MS) are two examples of areas subject to particularly heavy control. This fact sheet, with analytics commissioned by Pharmaceutical Research and Manufacturers of America (PhRMA), highlights formulary restrictions, payer restrictions, cost-sharing assistance utilization rates and other analyses from IQVIA's Market Access Strategy Consulting team.